Tlrl c264e 5

The following TLR agonists were used: TLR1/TLR2 agonist Pam3CSK4 (#tlrl-pms, InvivoGen, San Diego, CA, USA); TLR3 agonist polyinosinic:polycytidylic acid [poly(I:C)] of high molecular weight type (#tlrl-pic, InvivoGen); TLR4 agonist LPS from E. coli (#L4391, Sigma-Aldrich, St. Louis, MO, USA); and TLR7 agonist CL264 (#tlrl-c264e-5, InvivoGen). The TLR agonists were used alone or in combination with mouse recombinant IFN-γ (#315-05, Peprotech, Rocky Hill, NJ, USA), mouse recombinant IFN-β (#8234-MB, R&D Systems Inc., Minneapolis, MN USA), or mouse recombinant IFN-α type A (#12100-1, PBL Assay Sciences, Piscataway, NJ, USA).

The following TLR agonists were used: TLR1/TLR2 agonist Pam3CSK4 (Pam3, #tlrl-pms, InvivoGen, San Diego, CA, USA); TLR3 agonist poly(I:C) of high molecular weight type (#tlrl-pic, InvivoGen); TLR4 agonist LPS from E. coli (#L4391, Sigma-Aldrich); TLR5 agonist flagellin (FLA) from S. typhimurium, ultrapure type (#tlrl-epstfla-5, InvivoGen); TLR2/TLR6 agonist LTA from S. aureus (#L2515, Sigma-Aldrich); TLR7 agonist CL264 (#tlrl-c264e-5, InvivoGen); and TLR9 agonist CpG, class C ODN 2395 (#tlrl-2395-1, InvivoGen). The TLR agonists were used alone or in combination with mouse recombinant IFN-γ (#315-05, Peprotech, Rocky Hill, NJ, USA) at a 40 ng/ml concentration.